BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
Hospital Severo Ochoa
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Severo Ochoa (14)
2023
-
Myocardial revascularization failure among patients requiring cardiac catheterization and secondary revascularization in contemporary clinical practice: Results of the REVASEC multicenter registry
Catheterization and Cardiovascular Interventions, Vol. 102, Núm. 4, pp. 608-619
2022
-
Design and Rationale for a Real-World Prospective, Multicenter Registry of Myocardial Revascularization Failure and Secondary Revascularization: The REVASEC Study
Cardiovascular Revascularization Medicine, Vol. 40, pp. 50-56
-
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer
Oral Oncology, Vol. 134
2021
-
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 764-772
2020
-
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
Experimental Hematology and Oncology
2016
-
Multidisciplinary approach of unresectable head and neck cancer
Head and Neck Cancer: Multimodality Management, Second Edition (Springer International Publishing), pp. 617-624
2015
-
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 7, pp. 398-403
2014
-
Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: A multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study
British Journal of Haematology, Vol. 164, Núm. 5, pp. 668-674
-
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis
Leukemia Research, Vol. 38, Núm. 3, pp. 304-309
2011
-
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: Toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03)
Leukemia and Lymphoma, Vol. 52, Núm. 3, pp. 409-416
-
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Haematologica, Vol. 96, Núm. 10, pp. 1470-1477
2009
-
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide
Leukemia and Lymphoma, Vol. 50, Núm. 8, pp. 1283-1289
2008
-
Reacciones adversas relacionadas con la administración de inhibidores del TNF. Análisis de un registro de terapias biológicas
Reumatologia Clinica, Vol. 4, Núm. 3, pp. 90-95